ALT

Altimmune, Inc. Common Stock

$2.31

Current Price

All

AI analysis

Read what the AI thinks of Altimmune, Inc. Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

-$0.78

P/E

—

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Before the open · Expected EPS: -$0.14

Nov 10

Posts

No posts about ALT yet.

About Altimmune, Inc. Common Stock

Altimmune is a biotechnology company that develops experimental drugs, with a focus on treatments for liver disease and obesity-related conditions. It has no real product on the market yet, so it earns almost no revenue. It pays for its research by raising money from investors, and it only makes money if a drug passes clinical trials and wins approval.